<DOC>
	<DOCNO>NCT00280618</DOCNO>
	<brief_summary>Primary : - To determine Tumor Response Rate patient hepatocellular carcinoma treat combination chemotherapy Eloxatin+5-Fluorouracil/Leucovorin Secondary : - Safety tolerability regimen patient</brief_summary>
	<brief_title>Oxaliplatin Unresectable Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients must histologically confirm hepatocellular carcinoma Patients must measurable disease CT scan Patients unresectable , recurrent metastatic disease may chemonaive may previously treat chemotherapy . The period washout prior chemotherapy must great 4 week date randomization . The prior chemotherapy include platinum compound . WHO performance status : 0 2 Patients must adequate organ marrow function define : Leukocytes : ≥ 3,000/μl Absolute neutrophil count : ≥ 1,500/μl Platelets : ≥ 80,000/μl Total bilirubin : &lt; 3.0g/dl ASAT/ALAT : ≤ 3 time upper normal limit institute Creatinine : &lt; 120μmol/l Patients evidence clinically significant neuropathy . Documented allergy platinum compound others study 's drug Pregnant lactate woman woman childbearing potential ( e.g . use adequate contraception ) Hematological disorder malignancy Metastasis central nervous system Other serious illness medical condition : Active infectious disease Congestive heart failure , angina pectoris . Previous history myocardial infarction within 1 year study entry ; uncontrolled hypertension arrhythmia . Concurrent treatment anticancer therapy Concurrent treatment experimental drug . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>